Previous 10 | Next 10 |
2024-04-12 05:08:54 ET Summary Vertex Pharmaceuticals is the world's only provider of gene-based therapy for cystic fibrosis, with a $10 billion revenue business. The acquisition of Alpine Immune Sciences adds another therapy to Vertex's pipeline, potentially increasing the compan...
2024-04-11 16:48:36 ET Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were fi...
2024-04-11 15:23:48 ET Summary Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. Povetacicept has shown promising results in reducing protei...
2024-04-11 09:40:22 ET Summary Boston-based pharma giant Vertex Pharmaceuticais set to acquire Seattle-based biotech company Alpine Immune Sciences for $4.9 billion in cash. The acquisition was unanimously approved by both companies' boards of directors and is expected to close la...
2024-04-11 09:23:46 ET Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65? But shareholders of the ...
2024-04-11 09:15:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an inv...
2024-04-11 08:36:33 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Vertex enters into agreement to acquire Alpine Immune Sciences ...
2024-04-10 16:10:49 ET More on Vertex Pharmaceuticals Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth Vertex's NDS for its sickle cell disease and thalassemia treatment accepted for priority review by Health Canada Vertex expands kidney dise...
- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...